跳至主要内容
临床试验/PACTR202305669258195
PACTR202305669258195已完成2 期

Impact of the association of Tadalafil and Silodosin on the recurrence of acute urinary retention secondary to benign prostate hyperplasia:Randomized double-blind clinical trial

oghmari Ahmed0 个研究点目标入组 48 人开始时间: 2023年4月27日最近更新:

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
48

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
45 Year(s) 至 64 Year(s)(—)
性别
Male

入选标准

  • The study enrolled consenting male patients
  • Aged more than 45 years
  • Presenting acute urinary retention (AUR) (first episode) secondary to benign prostatic hyperplasia (BPH)
  • Not presenting personal history of AUR, prostate cancer, prostatectomy, tumorous duct obstruction, lower urinary tract infection, lower urinary tract surgery, AUR after surgery
  • With no simultaneous use of drugs having interactions with Tadalafil or Silodosine

排除标准

  • Patients who did not complete the follow-up
  • Patients in whom a significant prostatic protrusion index was discovered during the study
  • Patients in whom a bladder lithiasis, or bladder diverticulum were discovered

研究者

发起方
oghmari Ahmed

相似试验